Brief: Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026
11/03/2026 18:07
March 11 (Reuters) - BridgeBio Pharma Inc BBIO.O: BBP-418 DEMONSTRATES CONSISTENT EFFICACY AND FAVORABLE SAFETY PROFILE IN PHASE 3 FORTIFY INTERIM ANALYSIS IN LGMD2I/R9 BRIDGEBIO PHARMA INC - TO SUBMIT NDA FOR BBP-418 TO FDA IN H1 2026 BRIDGEBIO PHARMA INC - BBP-418 WELL TOLERATED WITH SAFETY PROFILE COMPARABLE TO PLACEBO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels